Who owns LYELL IMMUNOPHARMA INC COM NEW?
- Ticker: LYEL
- CUSIP Number: 55083r203
Tip: Access positions for across all investors
Analyze quarterly positions in Lyell Immunopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Lyell Immunopharma stock
Who bought or sold LYELL IMMUNOPHARMA INC COM NEW this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Arch Venture Corp | 3.2M | $65M | 18% | Mar 2026 |
|
| Foresite Capital Management IV | 800k | $16M | 0% | Mar 2026 |
|
| Orland Properties | 755k | $15M | 0% | Mar 2026 |
|
| Vanguard Capital Management | 718k | $14M | 100% | Mar 2026 |
|
| Almitas Capital | 578k | $12M | 0% | Mar 2026 |
|
| Foresite Capital Management V | 477k | $9.6M | 0% | Mar 2026 |
|
| Millennium Management | 459k | $9.2M | 682% | Mar 2026 |
|
| Citadel Advisors | 394k | $7.9M | 15% | Mar 2026 |
|
| venBio Partners | 338k | $6.8M | 0% | Mar 2026 |
|
| Susquehanna International | 310k | $6.2M | 95% | Mar 2026 |
|
| Alphabet | 293k | $5.9M | 0% | Mar 2026 |
|
| BlackRock | 192k | $3.8M | 5% | Mar 2026 |
|
| Geode Capital Management | 167k | $3.4M | 2% | Mar 2026 |
|
| Sc China Holding | 152k | $73k | 0% | Mar 2026 |
|
| Marshall Wace | 149k | $3.0M | 103% | Mar 2026 |
|
| Renaissance Technologies | 116k | $2.3M | 195% | Mar 2026 |
|
| Goldman Sachs Group | 115k | $2.3M | 18% | Mar 2026 |
|
| Velan Capital Investment Management | 102k | $2.0M | 100% | Mar 2026 |
|
| MIC Capital Management UK | 87k | $1.7M | 0% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 87k | $1.7M | 100% | Mar 2026 |
|
| Charles Schwab Investment Management | 86k | $1.7M | 1% | Mar 2026 |
|
| Opaleye Management | 79k | $1.6M | 100% | Mar 2026 |
|
| State Street Corporation | 73k | $1.5M | 41% | Mar 2026 |
|
| Jane Street | 64k | $1.3M | 415% | Mar 2026 |
|
| Morgan Stanley | 56k | $1.1M | 31% | Mar 2026 |
|
| Qube Research & Technologies | 55k | $1.1M | 509% | Mar 2026 |
|
| Dimensional Fund Advisors | 48k | $961k | 100% | Mar 2026 |
|
| Rbf Capital | 44k | $885k | -41% | Mar 2026 |
|
| Ikarian Capital | 41k | $824k | 0% | Mar 2026 |
|
| Hartland & Co | 40k | $801k | 100% | Mar 2026 |
|
| Bank of America Corporation | 33k | $668k | 100% | Mar 2026 |
|
| UBS Group | 32k | $638k | 141% | Mar 2026 |
|
| Northern Trust | 30k | $607k | 0% | Mar 2026 |
|
| Canada Pension Plan Investment Board | 29k | $590k | -8% | Mar 2026 |
|
| Vanguard Portfolio Management | 23k | $462k | 100% | Mar 2026 |
|
| Walleye Trading Advisors | 22k | $446k | 100% | Mar 2026 |
|
| Point72 Asset Management | 21k | $427k | 85% | Mar 2026 |
|
| Susquehanna Portfolio Strategies | 21k | $417k | 0% | Mar 2026 |
|
| Jump Financial | 20k | $404k | 100% | Mar 2026 |
|
| Squarepoint Ops | 19k | $387k | 100% | Mar 2026 |
|
| Bridgeway Capital Management | 18k | $361k | 0% | Mar 2026 |
|
| American Century Companies | 16k | $320k | 100% | Mar 2026 |
|
| Brevan Howard Capital Management | 13k | $270k | 100% | Mar 2026 |
|
| Two Sigma Investments | 12k | $232k | -26% | Mar 2026 |
|
| Citigroup | 5.9k | $119k | 100% | Mar 2026 |
|
| Vanguard Global Advisers | 5.2k | $104k | 100% | Mar 2026 |
|
| Diadema Partners | 4.1k | $82k | 8% | Mar 2026 |
|
| China Universal Asset Management | 3.8k | $76k | 9% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 2.1k | $42k | -34% | Mar 2026 |
|
| FMR | 1.8k | $37k | 0% | Mar 2026 |
|
| Barclays | 1.7k | $34k | -90% | Mar 2026 |
|
| Tower Research Capital | 1.3k | $26k | 9% | Mar 2026 |
|
| Mirae Asset Global Investments | 1.1k | $22k | 7% | Mar 2026 |
|
| Jones Financial Companies, L.L | 1.0k | $20k | 0% | Mar 2026 |
|
| Simplex Trading | 693.00 | $14k | 1773% | Mar 2026 |
|
| IFP Advisors | 648.00 | $13k | 100% | Mar 2026 |
|
| Advisors Asset Management | 567.00 | $11k | 0% | Mar 2026 |
|
| Gf Fund Management | 470.00 | $9.4k | 13% | Mar 2026 |
|
| Zurcher Kantonalbank | 447.00 | $9.0k | 100% | Mar 2026 |
|
| Royal Bank of Canada | 251.00 | $5.6k | 100% | Mar 2026 |
|
| Seneschal Advisors | 126.00 | $2.5k | 100% | Mar 2026 |
|
| Wells Fargo & Company | 125.00 | $2.5k | 0% | Mar 2026 |
|
| Advisor Group Holdings | 124.00 | $2.5k | 0% | Mar 2026 |
|
| Group One Trading | 100.00 | $2.0k | 100% | Mar 2026 |
|
| MAI Wealth Advisors | 100.00 | $2.0k | 0% | Mar 2026 |
|
| Cornerstone Financial Management | 46.00 | $922.999200 | 100% | Mar 2026 |
|
| Hanson McClain Advisors | 43.00 | $863.001400 | 100% | Mar 2026 |
|
| GAMMA Investing | 35.00 | $491.998500 | 0% | Jun 2026 |
|
| NISA Investment Advisors | 25.00 | $502.000000 | 0% | Mar 2026 |
|
| Persistent Asset Partners | 10.00 | $27k | 100% | Mar 2026 |
|
| CWM | 2.00 | $40.000000 | -90% | Mar 2026 |
|
Who sold out of Lyell Immunopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Invesco | Dec 2025 | 99k | $3.0M |
| Johnson & Johnson | Dec 2025 | 55k | $1.7M |
| Boothbay Fund Management | Dec 2025 | 9.5k | $293k |
| ExodusPoint Capital Management | Dec 2025 | 8.5k | $262k |
| Raymond James Financial | Dec 2025 | 7.9k | $243k |
| Candriam Luxembourg S.C.A. | Dec 2025 | 7.6k | $235k |
| BBR Partners | Dec 2025 | 6.8k | $210k |
| Acadian Asset Management | Dec 2025 | 1.7k | $51k |
| Daiwa Securities Group | Dec 2025 | 45.00 | $999.999000 |